Embecta (EMBC) Competitors $9.94 +0.19 (+1.99%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. WRBY, NVCR, ENOV, LMAT, EYE, CNMD, AORT, CDRE, ESTA, and TNDMShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Warby Parker (WRBY), NovoCure (NVCR), Enovis (ENOV), LeMaitre Vascular (LMAT), National Vision (EYE), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors Warby Parker NovoCure Enovis LeMaitre Vascular National Vision CONMED Artivion Cadre Establishment Labs Tandem Diabetes Care Warby Parker (NYSE:WRBY) and Embecta (NASDAQ:EMBC) are both medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Does the media prefer WRBY or EMBC? In the previous week, Warby Parker had 2 more articles in the media than Embecta. MarketBeat recorded 9 mentions for Warby Parker and 7 mentions for Embecta. Embecta's average media sentiment score of 0.71 beat Warby Parker's score of 0.14 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, WRBY or EMBC? Embecta has higher revenue and earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWarby Parker$795.09M3.08-$20.39M-$0.12-195.25Embecta$1.08B0.54$78.30M$0.9011.02 Which has more volatility & risk, WRBY or EMBC? Warby Parker has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Is WRBY or EMBC more profitable? Embecta has a net margin of 4.89% compared to Warby Parker's net margin of -1.79%. Warby Parker's return on equity of -2.48% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Warby Parker-1.79% -2.48% -1.29% Embecta 4.89%-19.67%12.27% Do analysts recommend WRBY or EMBC? Warby Parker currently has a consensus price target of $22.88, indicating a potential downside of 2.37%. Embecta has a consensus price target of $19.00, indicating a potential upside of 91.63%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Warby Parker 0 Sell rating(s) 9 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders believe in WRBY or EMBC? 93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 18.2% of Warby Parker shares are owned by insiders. Comparatively, 0.4% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryEmbecta beats Warby Parker on 9 of the 16 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$574.50M$7.02B$5.52B$9.35BDividend Yield6.26%2.88%4.25%4.09%P/E Ratio10.9224.3027.9519.83Price / Sales0.5432.06438.79106.18Price / Cash2.8725.3335.5357.53Price / Book-0.778.168.255.72Net Income$78.30M$236.06M$3.23B$257.51M7 Day Performance-7.33%-2.67%-0.13%0.59%1 Month Performance1.06%1.67%7.21%10.74%1 Year Performance-26.88%18.93%27.45%15.87% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.6888 of 5 stars$9.92+1.7%$19.00+91.6%-26.1%$574.50M$1.08B10.922,100Analyst ForecastWRBYWarby Parker2.4843 of 5 stars$21.40-3.8%$22.88+6.9%+32.9%$2.32B$771.32M-178.333,780NVCRNovoCure3.4035 of 5 stars$16.89-4.6%$32.83+94.4%-14.0%$1.97B$605.22M-11.191,488Upcoming EarningsENOVEnovis2.5299 of 5 stars$33.03-1.8%$58.00+75.6%-34.2%$1.92B$2.11B10.727,367Positive NewsLMATLeMaitre Vascular2.6864 of 5 stars$82.98-1.7%$97.83+17.9%-5.1%$1.91B$219.86M41.91490News CoveragePositive NewsEYENational Vision2.8701 of 5 stars$23.33-2.4%$18.67-20.0%+83.9%$1.89B$1.82B-70.6913,411Positive NewsCNMDCONMED4.3294 of 5 stars$51.86-4.5%$62.20+19.9%-32.2%$1.68B$1.31B13.653,900News CoverageAORTArtivion2.3626 of 5 stars$30.22-1.6%$32.40+7.2%+10.6%$1.31B$388.54M122.881,600CDRECadre2.956 of 5 stars$31.84-1.2%$37.50+17.8%-16.4%$1.31B$567.56M33.932,284ESTAEstablishment Labs2.4012 of 5 stars$46.11+5.9%$52.40+13.6%-10.9%$1.26B$166.02M-14.871,018News CoverageAnalyst ForecastTNDMTandem Diabetes Care4.2116 of 5 stars$16.25-3.2%$33.43+105.7%-66.5%$1.12B$940.20M-5.852,650Positive NewsAnalyst Revision Related Companies and Tools Related Companies WRBY Alternatives NVCR Alternatives ENOV Alternatives LMAT Alternatives EYE Alternatives CNMD Alternatives AORT Alternatives CDRE Alternatives ESTA Alternatives TNDM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EMBC Stock Alerts